Alcon receives FDA approval for first-line use of Travatan Z
HUENENBERG, Switzerland — The U.S. Food and Drug Administration has approved Travatan Z ophthalmic solution for first-line treatment to lower IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release from Alcon, the developer of the once-daily eye drop.
"The FDA approval for first-line use of Travatan Z solution will allow eye care professionals to start newly diagnosed glaucoma and ocular hypertension patients with a product that is already well-received in the marketplace because of its efficacy and safety," Stuart Raetzman, Alcon's vice president of global marketing and area president for the United States, said in the release. "This approval also means that Travatan Z will be the first and only prostaglandin analogue approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride (BAK)."
Travatan Z (travoprost ophthalmic solution 0.004%) with the preservative system sofZia was first introduced in the U.S. in 2006.